Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05039840 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 20
- Study locations
NCT05039840 is a Phase 2 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by Sanofi. The registered enrollment target is 116 participants, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05039840, a Phase 2 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Conditions Studied
Interventions
- DRUG SAR441344 IV
- DRUG SAR441344 SC
- DRUG Placebo IV
- DRUG Placebo SC
Study Locations (20)
Florida
- Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400002 - DeBary
- Vitalia Medical Research - Margate- Site Number : 8400039 - Margate
- Innovia Research Center- Site Number : 8400037 - Miramar
- Integral Rheumatology and Immunology Specialists- Site Number : 8400014 - Plantation
- Infigo Clinical Research- Site Number : 8400016 - Sanford
Arizona
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler- Site Number : 8400026 - Chandler
- Arizona Arthritis & Rheumatology Associates - South Vineyard Avenue- Site Number : 8400022 - Mesa
- Arizona Arthritis & Rheumatology Research - Sun City- Site Number : 8400027 - Sun City
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast- Site Number : 8400023 - Tucson
Texas
- Tekton Research - West Gate- Site Number : 8400001 - Austin
- Precision Comprehensive Clinical Research Solutions - Colleyville- Site Number : 8400017 - Colleyville
- Lone Start Arthritis & Rheumatology Associates- Site Number : 8400025 - Fort Worth
- Prolato Clinical Research Center- Site Number : 8400005 - Houston
California
- Saint John's Physician Partners- Site Number : 8400015 - Santa Monica
- Millennium Clinical Trials - Simi Valley- Site Number : 8400004 - Simi Valley
Alabama
- Accel Research Sites Network - Birmingham- Site Number : 8400003 - Vestavia Hills
New Mexico
- Inspire Santa Fe Medical Group- Site Number : 8400019 - Santa Fe
New York
- Columbia University Irving Medical Center- Site Number : 8400009 - New York
Oklahoma
- RAO - Rheumatology Associates of Oklahoma- Site Number : 8400013 - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2026-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05039840
The ClinicalTrials.gov registry entry for NCT05039840 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (69% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 4 interventions - of which SAR441344 IV is the first listed.
NCT05039840 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT05039840 about?
NCT05039840 is a clinical study titled "Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus". This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study detail...
What is the current status of trial NCT05039840?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2021-11-10. Estimated completion is 2026-10-02.
What conditions does trial NCT05039840 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT05039840?
The interventions under investigation include: SAR441344 IV (DRUG), SAR441344 SC (DRUG), Placebo IV (DRUG), Placebo SC (DRUG).
Who is sponsoring clinical trial NCT05039840?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05039840 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.